Clinical Trial

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2023-03-13; most recent amendment 2025-11-12.
Status change: Not Yet Recruiting → Recruiting 2024-02-15
Trial Details
NCT Number NCT05783323
Lead Sponsor Children's Hospital of Philadelphia
Collaborators: Bayer
Conditions Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
Enrollment 13 participants
Start Date 2024-02-14
Primary Completion 2026-10-01 (estimated)
Study Completion 2027-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-14